Amneal Pharmaceuticals has been awarded 180 days of competitive generic therapy exclusivity as it received approval from the US Food and Drug Administration for its generic version of aminocaproic acid 0.25g/ml oral solution. Amneal’s rival to Amicar - used to treat severe bleeding caused by problems with the blood clotting system - was previously granted a CGT designation by the FDA.
Draft guidance on the CGT pathway was published by the FDA earlier this year “to encourage generic entry for drugs...




